BSD Medical has received an initial purchase order from its exclusive Taiwan distributor Linden Bioscence to supply four BSD-2000 Hyperthermia Systems (BSD-2000).
Developed and patented by BSD Medical, the BSD-2000 delivers localized therapeutic heating by applying radiofrequency (RF) energy.
The BSD-2000 creates a central focusing of energy that can be focused to target the shape, size and location of the tumor electronically, resulting in providing dynamic control of the heating delivered to the tumor region.
The purchase order was placed with a substantial advance deposit.
The shipment of BSD-2000 will commence with Linden’s receipt of Taiwan Food and Drug Administration (TFDA) import license approval, which could occur in November 2013.
BSD Medical president Harold Wolcott said that the agreement with Linden and its commitment to make the BSD-2000 a success in Taiwan is a notable achievement.